New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
09:07 EDTGLYC, AZNGlycoMimetics appoints Pearson to board
GlycoMimetics (GLYC) announced the addition of Timothy Pearson to its board of directors. Pearson most recently held the position of CFO, executive vice president and treasurer at Catalyst Health Solutions. Pearson had previously served as CFO and executive vice president of medImmune, the global biologics business for AstraZeneca (AZN).
News For GLYC;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
09:02 EDTGLYCGlycoMimetics announces publication of Phase 2 rivipansel data in sickle cell
GlycoMimetics announced the publication of results from a randomized, placebo-controlled Phase 2 investigational study evaluating the efficacy, safety and pharmacokinetics of rivipansel in patients with sickle cell disease hospitalized for a vaso-occlusive crisis. Study results were pre-published online by Blood,1 the journal of the American Society of Hematology. The article, entitled “Randomized Phase 2 Study of GMI-1070 in SCD: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use,” highlights rivipansel’s potential to improve clinical outcomes in sickle cell patients experiencing VOC. Results from the study were previously highlighted in two oral presentations and one poster presentation at the December 2013 ASH Annual Meeting and Exposition.
March 2, 2015
09:02 EDTAZNAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
February 27, 2015
06:24 EDTAZNAstraZeneca turning antibiotic R&D into separate subsidiary, Reuters reports
Subscribe for More Information
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
February 20, 2015
07:23 EDTAZNAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use